These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17160795)

  • 1. The need for radiologists' awareness of nephrogenic systemic fibrosis.
    Aydingöz U
    Diagn Interv Radiol; 2006 Dec; 12(4):161-2. PubMed ID: 17160795
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of gadolinium in triggering nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy.
    Solomon GJ; Rosen PP; Wu E
    Arch Pathol Lab Med; 2007 Oct; 131(10):1515-6. PubMed ID: 17922586
    [No Abstract]   [Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide.
    Thomsen HS
    Eur Radiol; 2006 Dec; 16(12):2619-21. PubMed ID: 17061066
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis:
    Alabousi M; Davenport MS
    Radiology; 2021 Aug; 300(2):279-284. PubMed ID: 34060939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.
    Leiner T; Herborn CU; Goyen M
    Eur Radiol; 2007 Aug; 17(8):1921-3. PubMed ID: 17458550
    [No Abstract]   [Full Text] [Related]  

  • 7. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis.
    Marckmann P; Skov L; Rossen K; Thomsen HS
    Clin Nephrol; 2008 Mar; 69(3):161-8. PubMed ID: 18397714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis in stage 4 kidney disease, what is the alternative?
    Stassen PM
    Neth J Med; 2008 Mar; 66(3):132; author reply 133. PubMed ID: 18349472
    [No Abstract]   [Full Text] [Related]  

  • 13. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
    Grobner T
    Nephrol Dial Transplant; 2006 Apr; 21(4):1104-8. PubMed ID: 16431890
    [No Abstract]   [Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent.
    Clorius S; Technau K; Watter T; Schwertfeger E; Fischer KG; Walz G; Gerke P
    Clin Nephrol; 2007 Oct; 68(4):249-52. PubMed ID: 17969494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis following gadolinium administration.
    Tammaro A; Narcisi A; Tuchinda P; Sina B
    Cutis; 2015 Jul; 96(1):E23-5. PubMed ID: 26244362
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to editorial: animal models for nephrogenic systemic fibrosis.
    Sieber MA; Lengsfeld P; Pietsch H
    Acta Radiol; 2008 Oct; 49(8):963-4. PubMed ID: 18798020
    [No Abstract]   [Full Text] [Related]  

  • 18. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 20. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.